Arena Pharmaceuticals, Inc. (ARNA): Price and Financial Metrics


Arena Pharmaceuticals, Inc. (ARNA): $91.24

1.45 (+1.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 450

in industry

ARNA POWR Grades


  • Sentiment is the dimension where ARNA ranks best; there it ranks ahead of 27.88% of US stocks.
  • ARNA's strongest trending metric is Quality; it's been moving down over the last 169 days.
  • ARNA ranks lowest in Stability; there it ranks in the 6th percentile.

ARNA Stock Summary

  • Arena Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.58% of US listed stocks.
  • With a price/sales ratio of 148,828.9, Arena Pharmaceuticals Inc has a higher such ratio than 100% of stocks in our set.
  • As for revenue growth, note that ARNA's revenue has grown -98.87% over the past 12 months; that beats the revenue growth of just 0.7% of US companies in our set.
  • Stocks that are quantitatively similar to ARNA, based on their financial statements, market capitalization, and price volatility, are SVRA, ADCT, FSR, BLU, and NYMX.
  • ARNA's SEC filings can be seen here. And to visit Arena Pharmaceuticals Inc's official web site, go to www.arenapharm.com.

ARNA Valuation Summary

  • ARNA's price/sales ratio is 56703.5; this is 499490.31% higher than that of the median Healthcare stock.
  • ARNA's price/earnings ratio has moved up 126.3 over the prior 243 months.
  • ARNA's price/earnings ratio has moved up 126.3 over the prior 243 months.

Below are key valuation metrics over time for ARNA.

Stock Date P/S P/B P/E EV/EBIT
ARNA 2021-08-31 56703.5 3.3 -6.7 -5.8
ARNA 2021-08-30 55449.1 3.3 -6.5 -5.6
ARNA 2021-08-27 56177.2 3.3 -6.6 -5.7
ARNA 2021-08-26 54387.7 3.2 -6.4 -5.5
ARNA 2021-08-25 54710.5 3.2 -6.4 -5.5
ARNA 2021-08-24 54207.0 3.2 -6.4 -5.5

ARNA Growth Metrics

    Its year over year cash and equivalents growth rate is now at 127.37%.
  • The 2 year cash and equivalents growth rate now stands at -63.11%.
  • Its 5 year price growth rate is now at 215.51%.
ARNA's revenue has moved down $17,933,000 over the prior 33 months.

The table below shows ARNA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 0.037 -437.903 -582.985
2021-06-30 0.057 -395.123 -484.111
2021-03-31 0.057 -379.038 -422.944
2020-12-31 0.319 -353.094 -404.734
2020-09-30 3.284 -308.139 -370.884
2020-06-30 4.614 -285.642 -346.311

ARNA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ARNA has a Quality Grade of C, ranking ahead of 63.92% of graded US stocks.
  • ARNA's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • MRSN, CRBP, and ARWR are the stocks whose asset turnover ratios are most correlated with ARNA.

The table below shows ARNA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 1 -0.626
2021-03-31 0.000 1 -0.505
2020-12-31 0.000 1 -0.462
2020-09-30 0.003 1 -0.425
2020-06-30 0.004 1 -0.368
2020-03-31 0.005 1 -0.316

ARNA Price Target

For more insight on analysts targets of ARNA, see our ARNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $95.25 Average Broker Recommendation 1.34 (Strong Buy)

ARNA Stock Price Chart Interactive Chart >

Price chart for ARNA

ARNA Price/Volume Stats

Current price $91.24 52-week high $94.23
Prev. close $89.79 52-week low $45.50
Day low $89.65 Volume 1,032,200
Day high $91.26 Avg. volume 1,583,900
50-day MA $79.39 Dividend yield N/A
200-day MA $65.90 Market Cap 5.62B

Arena Pharmaceuticals, Inc. (ARNA) Company Bio


Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing drugs to address unmet medical needs. The company was founded in 1997 and is based in San Diego, California.


ARNA Latest News Stream


Event/Time News Detail
Loading, please wait...

ARNA Latest Social Stream


Loading social stream, please wait...

View Full ARNA Social Stream

Latest ARNA News From Around the Web

Below are the latest news stories about Arena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARNA as an investment opportunity.

Activision Blizzard Trades At A 13% Discount To Microsoft's Purchase Offer; Expect That Gap To Partially Close Soon

Activision Blizzard, Inc. (ATVI) rose 26% on Tuesday after Microsoft Corporation (MSFT) announced that it will be purchasing the company for $95.00 per share in an all-cash deal. That 26% rise resulted in an $82.31 close, 13% below the offer price and down from the initial $86.76 open. In this...

Edward Vranic, CFA on Seeking Alpha | January 19, 2022

Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ...

Investment company Asymmetry Capital Management, L.P. (Current Portfolio) buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, AbbVie Inc, IQVIA Holdings Inc, Centene Corp, sells Alkermes PLC, Medtronic PLC, Insulet Corp, Hologic Inc, Sage Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Asymmetry Capital Management, L.P..

Yahoo | January 19, 2022

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PARK CITY, Utah, January 18, 2022--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement restricted stock units ("RSUs") to new employees. The inducement RSUs have a grant date and vesting commencement date of January 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). These grants included:

Yahoo | January 18, 2022

7 Long-Term Stocks to Buy and Hold Until 2030

Long-term stocks that promise to be value creators with a robust business model and positive industry tailwinds.

Faisal Humayun on InvestorPlace | January 17, 2022

Zynga Trades At A 10% Discount To Take-Two's Purchase Offer; Expect That Gap To Partially Close Soon

Zynga Inc. (ZNGA) rose 41% on Monday after Take-Two Interactive Software, Inc. (TTWO) announced that it will be purchasing the company for $9.86 per share. However, that 41% rise resulted in an $8.44 close, 14% below the supposed take-out target and down from the initial $8.90 open. In this article,...

Edward Vranic, CFA on Seeking Alpha | January 11, 2022

Read More 'ARNA' Stories Here

ARNA Price Returns

1-mo -1.79%
3-mo 58.98%
6-mo 50.83%
1-year 22.90%
3-year 102.98%
5-year 529.24%
YTD -1.83%
2021 20.97%
2020 69.15%
2019 16.61%
2018 14.66%
2017 139.23%

Continue Researching ARNA

Want to see what other sources are saying about Arena Pharmaceuticals Inc's financials and stock price? Try the links below:

Arena Pharmaceuticals Inc (ARNA) Stock Price | Nasdaq
Arena Pharmaceuticals Inc (ARNA) Stock Quote, History and News - Yahoo Finance
Arena Pharmaceuticals Inc (ARNA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7669 seconds.